Suven to present data on SUVN 502 at UK conference
Hyderabad, Oct 13 (UNI) Suven Life Sciences, a biopharmaceutical company, today announced it would present data on Phase I clinical trial candidate SUVN 502 for cognition in Alzheimer's and Schizophrenia at the '16th Annual Bio Partnering Europe' meet tomorrow.
Besides, Suven Life Sciences CEO Venkat Jasti will discuss company's business strategy and corporate overview at the QE11 Conference Centre at London.
The company has six internally discovered therapeutic drug candidates currently in clinical and pre-clinical stage of development targeting conditions such as ADHD, dementia and depression, Parkinson's disease, a press release here said.
UNI VA GM 1451
More From
-
Gold Rate Today, 10 March 2026: Check IBJA Gold Prices, Retail Rates At Tanishq, Malabar, Joyalukkas, Kalyan -
Gold Silver Rate Today, 9 March 2026: City-Wise Prices, MCX Gold and Silver Ease Slightly After Rally -
Bangalore Gold Silver Rate Today, March 9, 2026: Gold and Silver Prices Fall as US Dollar Strengthens -
Vijay-Trisha's Secret Marriage Photo Leaked Online? Is The Wedding Photo Real Or Fake? -
Chennai MRTS Velachery–St Thomas Mount Line Opening on March 10 Faces Delay; Direct Beach Route to Start Later -
Kerala Election 2026 Date: When Can You Expect EC To Announce Key Dates of Voting & Counting? -
Gas Supply Squeeze May Leave 10 Lakh Bengaluru PG Residents Without Daily Meals -
Gold Silver Rate Today, 10 March 2026: City-Wise Prices Edge Lower While MCX Gold And Silver Stay Range-Bound -
Who Was Mojtaba Khamenei’s Wife Zahra Haddad-Adel and What Do We Know About Her? -
Vijay-NDA Alliance On Cards? Pawan Kalyan Reportedly Reaches Out to TVK Chief -
Who Is Aditi Hundia? Viral ‘Girl in Red’ & Ishan Kishan's Girlfriend Spotted During IND vs NZ Final -
Hyderabad Gold Silver Rate Today, 9 March 2026: Latest 24K, 22K Gold And Silver Rates In City
Click it and Unblock the Notifications
Sign in with Google